Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
Conference call scheduled for 4:30 p.m. Eastern Time
東部時間下午4:30安排了電話會議
WALTHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, October 31, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the third quarter of 2024.
馬薩諸塞州沃爾瑟姆，2024年10月17日（環球新聞社）-- ardelyx, Inc.（納斯達克: ARDX）是一家生物製藥公司，致力於發現、開發和商業化創新的、首創類藥物，滿足重大未滿足的醫療需求。今天宣佈將於2024年10月31日星期四東部時間下午4:30召開電話會議，討論2024年第三季度的財務業績並提供業務更新。
To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at . The webcast will be archived and available for replay for 30 days following the call.
要參加電話會議，請撥打(877) 346-6112（國內）或(848) 280-6350（國際），並要求加入ardelyx的會議。電話會議的現場音頻將與網絡同步播出，並可在公司網站的投資者部分查看。網絡直播將存檔，並在電話會議後的30天內供回放。
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA (tenapanor) and XPHOZAH (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
關於Ardelyx
Ardelyx致力於發現、開發並商業化創新的、首創的藥物，以滿足重大未滿足的醫療需求。Ardelyx在美國有兩個商業化產品獲得批准，即IBSRELA（tenapanor）和XPHOZAH（tenapanor）。Ardelyx已經達成在美國以外地區開發和商業化tenapanor的協議。Kyowa Kirin在日本商業化PHOZEVEL（tenapanor）用於治療高磷血癥。Fosun Pharma已經提交了治療高磷血癥tenapanor的新藥申請。Knight Therapeutics在加拿大商業化IBSRELA。欲了解更多信息，請訪問公司的網站，並添加我們的X (曾用名Twitter)、LinkedIn和Facebook聯繫我們。
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
投資者和媒體聯繫人：
Caitlin Lowie
clowie@ardelyx.com
譯文內容由第三人軟體翻譯。
